Welcome to our dedicated page for Champions Oncolo SEC filings (Ticker: CSBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Champions Oncology, Inc. (NASDAQ: CSBR) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its oncology research services and data businesses. Its common stock is registered on The Nasdaq Stock Market LLC, and the company reports financial and operational information under the Exchange Act. On this page, Stock Titan aggregates CSBR’s SEC filings and applies AI-powered summaries to help interpret the disclosures.
Current reports on Form 8-K from Champions Oncology frequently present results of operations and financial condition, including quarterly and annual oncology revenue, oncology services profit and oncology services margin, along with reconciliations of non-GAAP measures such as adjusted EBITDA and adjusted EPS to GAAP net income and earnings per share. Other 8-K filings describe corporate events such as the appointment of a new Chief Executive Officer, related employment agreements and leadership transitions at the board level.
The company’s definitive proxy statement on Schedule 14A outlines governance and compensation matters, including the election of directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation. It also describes the annual meeting process and voting requirements for stockholders.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, referenced in the company’s press releases, contain audited and unaudited financial statements, segment information related to oncology revenue and additional details on research services and data license revenue. Stock Titan’s CSBR filings page provides real-time access to these documents as they are posted to EDGAR, while AI-generated highlights help users quickly locate key topics such as non-GAAP reconciliations, oncology services margins, leadership changes and shareholder voting items.
Champions Oncology (CSBR) reported a director’s equity grant on a Form 4. The reporting person acquired an option to purchase 13,790 shares of common stock on 11/05/2025 at an exercise price of $6.80 per share. The option expires 11/05/2035 and vests over twelve months in four tranches on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026. Ownership is listed as Direct. This filing reflects routine director equity compensation and does not indicate cash proceeds to the company.
Champions Oncology (CSBR) insider activity: a director and 10% owner reported an award of derivative securities. On 11/05/2025, the reporting person acquired an option to purchase 25,460 shares of common stock at an exercise price of $6.80 per share, recorded as a Code A grant and held directly.
The options vest over twelve months in four dates—11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026—and are exercisable over ten years, with an expiration date of 11/05/2035.
Champions Oncology (CSBR) director reported a stock option grant. On 11/05/2025, the reporting person received 21,216 options to purchase common stock at an exercise price of $6.80 per share, with an expiration date of 11/05/2035.
The options vest over twelve months in four equal installments on Nov 5, 2025, Feb 5, 2026, May 5, 2026, and Aug 5, 2026. Following the transaction, 21,216 derivative securities were beneficially owned, reported as Direct (D) ownership.
Champions Oncology (CSBR) director Joel Ackerman reported an insider transaction on Form 4. On 10/30/2025, he exercised stock options for 94,405 shares at $2.1 per share (transaction code M), acquiring the same number of common shares.
After the transaction, he reported 1,056,539 shares beneficially owned directly and 0 derivative securities remaining. The exercised option covered 94,405 underlying shares with a $2.1 exercise price.
Champions Oncology (CSBR) reported results from its October 16, 2025 Annual Meeting. All seven director nominees were elected for one-year terms. The strongest director support was for Scott R. Tobin with 9,722,734 votes for.
Stockholders ratified the appointment of EisnerAmper LLP as independent auditor with 10,659,115 votes for. The non-binding advisory vote on executive compensation was approved with 9,720,681 votes for. Broker non-votes totaled 931,779 for proposals requiring them.
Champions Oncology, Inc. filed a current report to note that it issued a press release covering its unaudited financial results for the first quarter ended July 31, 2025. The press release is provided as Exhibit 99.1 to the report so investors can review the detailed quarterly information.
The company states that the information under this earnings item is being furnished, not filed, under securities law, which affects how it is treated for certain legal purposes and future SEC filings.
Champions Oncology, Inc. (CSBR) filed a Definitive Proxy Statement reporting governance, executive and compensation matters for the 2025 Annual Meeting. As of the record date of August 22, 2025, there were 13,788,421 shares outstanding and the meeting will be held at the company headquarters in Hackensack, New Jersey.
The filing discloses board composition and committee activity: the board has five independent and two non-independent directors, the board met two times during fiscal 2025, the Audit Committee (three independent members) met four times and identified Scott Tobin as the audit committee financial expert. The filing notes related-party consulting fees to a director who beneficially owned ~6.0% of shares, the unexpected death of President Brady Davis in October 2024, and that Robert Brainin will transition into a non-independent CEO role, necessitating committee membership changes. The Audit Committee recommends ratification of EisnerAmper LLP as auditor and the proxy includes a non-binding advisory vote on executive compensation.